Safety of l&#8208;tryptophan produced by fermentation with Escherichia&#160;coli CGMCC 7.59 for all animal species based on a dossier submitted by Feedway Europe NV by G. Aquilina et al.
SCIENTIFIC OPINION
ADOPTED: 9 March 2016
doi: 10.2903/j.efsa.2016.4444
Safety of L-tryptophan produced by fermentation with
Escherichia coli CGMCC 7.59 for all animal species based
on a dossier submitted by Feedway Europe NV
EFSA Panel on Additives and Products or Substances used in
Animal Feed (FEEDAP)
Abstract
L-Tryptophan is a feed additive produced by fermentation using a genetically modiﬁed strain of
Escherichia coli. The EFSA Panel on Additives and Products or Substances used in Animal Feed
(FEEDAP Panel) issued an opinion on the safety and efﬁcacy of the product, which concluded that ‘The
use of L-tryptophan produced by E. coli CGMCC 7.59 in feed is safe for non-ruminant target species
when supplemented to diets in appropriate amounts. As the metabolites of L-tryptophan produced by
ruminal bacteria may be toxic to the host animal, oral administration of unprotected L-tryptophan to
ruminants should be avoided. The Panel on Additives and Products or substances used in Animal Feed
(FEEDAP) has concerns about the safety of L-tryptophan for target species when administered via
water for drinking. . . . . .In the absence of any data on sensitisation, the product should be considered
a potential dermal sensitiser. The level of endotoxins present in the product and its dusting potential
indicate a health risk for the user upon inhalation’. The European Commission asked EFSA to deliver an
opinion on the safety of L-tryptophan, produced by an improved manufacturing process, as a
nutritional additive for all animal species based on additional data submitted by the applicant on
characterisation of the additive. The FEEDAP Panel reiterates its concern on the use of unprotected
tryptophan to ruminants and on the safety of the amino acid L-tryptophan for target species when
administered simultaneously via water for drinking. As the estimated maximum exposure to endotoxins
by inhalation of the improved product is below the provisional occupational exposure limit, no risk from
exposure to endotoxins for people handling the additive is expected. Concerns remain about possible
dermal sensitisation.
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Summary
Following a request from the European Commission (EC), the European Food Safety Authority
(EFSA) was asked to deliver a scientiﬁc opinion on the safety of L-tryptophan produced by
fermentation using the genetically modiﬁed strain Escherichia coli CGMCC 7.59 for all animal species.
In 2015, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP
Panel) adopted an opinion on the safety and efﬁcacy of L-tryptophan produced by fermentation using
E. coli CGMCC 7.59. In that opinion, the FEEDAP Panel concluded that ‘The use of L-tryptophan
produced by E. coli CGMCC 7.59 in feed is safe for non-ruminant target species when supplemented to
diets in appropriate amounts. As the metabolites of L-tryptophan produced by ruminal bacteria may be
toxic to the host animal, oral administration of unprotected L-tryptophan to ruminants should be
avoided. The Panel on Additives and Products or substances used in Animal Feed (FEEDAP) has
concerns about the safety of L-tryptophan for target species when administered via water for
drinking. . . . . .In the absence of any data on sensitisation, the product should be considered a potential
dermal sensitiser. The level of endotoxins present in the product and its dusting potential indicate a
health risk for the user upon inhalation’.
The applicant provided additional information in relation to the characterisation of the additive and
the production process. The FEEDAP Panel has performed the assessment of those new data following
an approach in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant
guidance documents.
This product is fully characterised in a previous scientiﬁc opinion; the additive does not give rise to
safety concerns with regard to the genetic modiﬁcations of the production strain.
In the former assessment, the FEEDAP Panel expressed its concerns about the safety of
L-tryptophan for target species when administered via water for drinking. Although the applicant states
that the additive will not be used in feed and in water for drinking at the same time, the FEEDAP
Panel has found no reason to modify its former conclusion.
The FEEDAP Panel reiterates its concern on the use of unprotected tryptophan to ruminants.
Due to improvements at several steps of the manufacturing process, the level of endotoxins
present in the product and its dusting potential have been reduced removing any health risk for the
user upon inhalation. The product should be considered a potential dermal sensitiser.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1831/2003 establishes rules governing the Community authorisation of additives
for animal nutrition and, in particular, Article 9 deﬁnes the terms of the authorisation by the Commission.
The applicant, Feedway Europe NV, is seeking a Community authorisation of L-tryptophan,
technically pure, to be used as a nutritional additive for all animal species (Table 1).
On 29 January 2015, the Panel on Additives and Products or Substances used in Animal Feed
(FEEDAP Panel) of the European Food Safety Authority (‘Authority’), in its opinion concluded that the
metabolites of L-tryptophan produced by ruminal bacteria may be toxic to the host animal, therefore
oral administration of unprotected L-tryptophan to ruminants should be avoided. The FEEDAP
Panel has concerns about the safety of L-tryptophan for target species when administered via water for
drinking due to possible amino acid imbalances. Finally, in the absence of any data on sensitisation,
the product should be considered a potential dermal sensitiser. The level of endotoxins present in the
product and its dusting potential indicate a health risk for the user upon inhalation.
The Commission gave the possibility to the applicant to submit complementary information in order
to complete the assessment on the safety and to allow a revision of Authority’s opinion.
The Commission has now received new data on the safety of L-tryptophan produced by
Escherichia coli CGMCC 7.59.
In view of the above, the Commission asks the Authority to deliver a new opinion on the safety of
L-tryptophan as nutritional additive for all animal species based on the additional data submitted by the
applicant.
1.2. Additional information
L-Tryptophan was ﬁrst authorised for use in animal nutrition by Directive 88/485/EEC. It is currently
authorised as a nutritional additive (functional group amino acids, their salts and analogues) for use in
all animal species without time limit and without maximum content in feed.
The applicant has provided additional information on the physical properties of the additive and on
the production process.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier1 following a previous application on the same product.2
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the characterisation and safety of
L-tryptophan produced by E. coli CGMCC 7.59 is in line with the principles laid down in Regulation (EC)
No 429/20083 and the relevant guidance documents: Guidance on nutritional additives (EFSA FEEDAP
Table 1: Description of the substances
Category of additive Nutritional additive
Functional group of additive Amino acids, their salts and analogues
Description L-Tryptophan, technically pure
Target animal category All animal species
Applicant Feedway Europe NV
Type of request New opinion
1 FEED dossier reference: FAD-2015-0031.
2 FEED dossier reference: FAD-2010-0287.
3 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
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Panel, 2012a) and Guidance on studies concerning the safety of use of the additive for users/workers
(EFSA FEEDAP Panel, 2012b).
3. Assessment
L-Tryptophan (minimum content of L-tryptophan 98%, ‘as is’ basis) was ﬁrst authorised for use in
animal nutrition by Directive 88/485/EEC. It is currently included in the European Union Register of
Feed Additives pursuant to Regulation (EC) No 1831/2003 concerning additives in feedingstuffs.
The current application is for the authorisation of L-tryptophan produced by a genetically modiﬁed
(GM) strain of E. coli (CGMCC 7.59), a derivative of E. coli K-12. It is intended to be used in all animal
species as a nutritional additive (functional group amino acids, their salts and analogues) to feed and
to water for drinking. The additive does not give rise to safety concerns with regard to the genetic
modiﬁcations of the production strain.
3.1. Characterisation
This product has been characterised in a previous scientiﬁc opinion (EFSA FEEDAP Panel, 2015).
Additional data have been submitted on the physical properties of the additive and on the
manufacturing process.
3.1.1. Impurities4
The endotoxin activity in three batches of the former product ranged from 0.36 to 1.12 IU/mg.5
The applicant stated that an improvement had been performed in the downstream process to reduce
the amount of bacterial endotoxins in the ﬁnal product. The ﬁltration by ceramic membrane has been
modiﬁed (from a former pore size of 300 kDa to the current smaller size of 20 kDa) and an additional
technique has been applied. New data have been submitted on the bacterial endotoxin activity of the
product, measured in three batches. The values ranged from 0.33 to 0.67 IU/mg (European
Pharmacopoeia 2.6.14 method).6
3.1.2. Physical properties
The applicant stated that the production process has been modiﬁed to increase the crystal size of
the ﬁnal product and consequently decrease its dustiness. The evaporation temperature has been
lowered (from 75 to 72°C), the evaporation rate reduced (from 2.5 to 2.0 m3/h), the evaporation time
prolonged (from 12 to 15 h) and the cooling time extended (from 3 to 5 h).
New analytical data have been provided to characterise the particle size and dustiness of the new
ﬁnal product. The particle size distribution (three batches analysed by laser diffraction) had a fraction
of 97.8% (v/v) particles < 100 lm, of 73.7% (v/v) of particles < 50 lm and 13.5% (v/v) of particles
< 10 lm of diameter.7 In the former product (six batches analysed by sieving), about 4% (w/w)
of particles had a diameter < 50 lm.8 The dusting potential (three batches analysed by
Stauber–Heubach) ranged from 0.81 to 1.21 g/m3.9 The dusting potential of the product assessed in
January 2015 (three batches) ranged from 3.9 to 4.2 g/m3.10
3.2. Safety
In its previous assessment the FEEDAP Panel, concluded that the additive is safe for the consumer
and the environment, but expressed some concerns regarding safety for the target animals and the
user (EFSA FEEDAP Panel, 2015).
4 This section has been amended following the applicable provisions on conﬁdentiality.
5 Technical dossier FAD-2010-0287/ Supplementary information, December 2014/Attachments 1–4.
6 Technical dossier/Technology improvement on production process, Supplementary information on endotoxin levels and
Attachments 1–3. According to the European Pharmacopoeia, monograph 01/2010:50110, the International Unit of endotoxin
is deﬁned as the speciﬁc activity of a deﬁned mass of the World Health Organization International Standard. One international
unit (IU) of endotoxin is equal to one endotoxin unit (EU).
7 Technical dossier/Supplementary information February 2016/Attachment 5.
8 Technical dossier FAD-2010-0287/Section II.1.5 and Annex II.1.2.
9 Technical dossier/Supplementary information February 2016/Annex 5.
10 Technical dossier FAD-2010-0287/Supplementary information January 2013/Attachment 8.
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3.2.1. Safety for the target species
In the former assessment, it was concluded that ‘the FEEDAP Panel has concerns about the safety
of L-tryptophan for target species when administered via water for drinking’. Although the applicant
states that the additive will not be used in feed and in water for drinking at the same time, the
FEEDAP Panel has found no reason to modify its former conclusion.
In its previous opinion, the Panel expressed concerns on the use of unprotected forms of
L-tryptophan in ruminants as the metabolites of L-tryptophan produced by ruminal bacteria may be
toxic to the host animals (EFSA FEEDAP Panel, 2015). No information has been provided by the
applicant in this regard and the FEEDAP Panel does not see a need to reconsider its conclusion.
3.2.2. Safety for the user
3.2.2.1. Effects on the skin
In its former assessment, the FEEDAP Panel concluded that ‘the product should be considered a
potential dermal sensitiser’. No new data have been submitted that could justify a change in that
conclusion.
3.2.2.2. Effects on the respiratory system
Although a previous assessment was performed in January 2015 (EFSA FEEDAP Panel, 2015), the
technological improvement in the manufacturing process makes necessary to re-assess the relevance
of the bacterial endotoxin activities found in the ﬁnal product for the user.
The bacterial endotoxin activity (the three new batches) is up to 0.67 IU/mg.11 The dusting
potential ranges from 0.81 to 1.21 g/m3.
The scenario used to estimate the exposure of persons handling the additive to endotoxins in
the dust, based on the EFSA Guidance on user safety (2012b), is described in Appendix A. The health-
based recommended threshold for the quantity of inhaled endotoxins per working day is 900 IU,
derived from provisional occupational exposure limits given by the Dutch Expert Committee on
Occupational Safety (DECOS) (Health Council of the Netherlands, 2010) and the Health and Safety
Executive (HSE, 2013). Based upon the calculation of the potential endotoxin content in dust (Wallace
et al., 2016), the inhalation exposure could be up to 455 endotoxin IU per 8-h working day, indicating
no risk from the exposure to endotoxins for people handling the additive.
3.2.2.3. Conclusions on safety for the user
The level of endotoxins present in the product and its dusting potential indicate no health risk for
the user upon inhalation. In the absence of any data on sensitisation, the product should be
considered a potential dermal sensitiser.
4. Conclusions
In the absence of new data, the Panel reiterates their concerns on target animal safety with regard
to the use of the additive in water and the use of unprotected forms in ruminants.
Due to improvements at several steps of the manufacturing process, the level of endotoxins
present in the product and its dusting potential have been reduced removing any health risk for the
user upon inhalation. The product should be considered a potential dermal sensitiser.
Documentation provided to EFSA
1) L-Tryptophan produced by Escherichia coli for all animal species. October 2015. Submitted by
Feedway Europe NV.
2) L-Tryptophan produced by Escherichia coli for all animal species. Supplementary information.
November 2015. Submitted by Feedway Europe NV.
3) L-Tryptophan produced by Escherichia coli for all animal species. Supplementary information.
February 2016. Submitted by Feedway Europe NV.
11 Technical dossier/Supplementary information on endotoxin levels and Attachments 1–3.
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HSE British Health and Safety Executive
IU International unit of endotoxin activity. One IU corresponds to one EU
L-Tryptophan produced by Escherichia coli for all animal species
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2016;14(5):4444
Appendix A – Safety for the user
The effects of endotoxin inhalation and the exposure limits have been described in a previous
opinion (EFSA FEEDAP Panel, 2015).
Calculation of maximum acceptable levels of exposure from feed additives
The probable exposure time according to EFSA guidance (EFSA FEEDAP Panel, 2012b) for additives
added in premixtures assumes a maximum of 40 periods of exposure per day, each comprising
20 s = 40 9 20 = 800 s/day. With an uncertainty factor of 2, maximum inhalation exposure would
occur for 2 9 800 = 1,600 s = 0.444 h/day. Again, assuming a respiration volume of 1.25 m3/h, the
inhalation volume providing exposure to potentially endotoxin-containing dust would be
0.444 9 1.25 = 0.556 m3/day. This volume should contain no more than 900 IU endotoxin, so the
dust formed from the product should contain no more than 900/0.556 = 1,619 IU/m3.
Calculation of endotoxin content of dust
Two key measurements are required to evaluate the potential respiratory hazard associated with
the endotoxin content of the product (the dusting potential of the product, expressed in g/m3, and the
endotoxin activity of the dust, determined by the Limulus amoebocyte lysate assay (expressed in
IU/g)). If data for the dust are not available, the content of endotoxins of the product can be
taken instead. If the content of endotoxins of the relevant additive is a IU/g and the dusting potential
is b g/m3, then the content of endotoxins of the dust, c IU/m3, is obtained by simple multiplication,
a 9 b. This resulting value is further used for calculation of the potential inhalatory exposure of users
to endotoxins from the additive under assessment (Table A.1) (EFSA FEEDAP Panel, 2012b).
Table A.1: Estimation of user exposure to endotoxins from the additive L-tryptophan produced by
Escherichia coli CGMCC 7.59, including consideration of using a ﬁlter mask FF P2 or
FF P3 as a preventative measure
Calculation Identiﬁer Description Amount Source
a Endotoxin content IU/g product 671 Technical dossier
b Dusting potential (g/m3) 1.21 Technical dossier
a 9 b c Endotoxin content in the air (IU/m3) 811.9
d No of premixture batches made/working day 40 EFSA FEEDAP
Panel (2012b)
e Time of exposure (s) per production of one
batch
20 EFSA FEEDAP
Panel (2012b)
d 9 e f Total duration of daily exposure/worker (s) 800
g Uncertainty factor 2 EFSA FEEDAP
Panel (2012b)
f 9 g h Reﬁned total duration of daily exposure/
worker (s)
1,600
h/3 600 i Reﬁned total duration of daily exposure (h) 0.44
j Inhaled air (m3) per 8-h working day 10 EFSA FEEDAP
Panel (2012b)
j/8 9 i k Inhaled air during exposure (m3) 0.56
c 9 k l Endotoxin inhaled during exposure per
8-h working day
455
m Health-based recommended exposure limit of
endotoxin (IU/m3) per 8-h working day
90 Health Council
of the Netherlands
(2010)
m 9 j n Health-based recommended exposure
limit of total endotoxin exposure (IU) per
8-h working day
900
l/10 Endotoxins inhaled (IU) per 8-h working day
reduced by ﬁlter mask FF P2 (reduction factor 10)
45
l/20 Endotoxins inhaled (IU) per 8-h working day
reduced by ﬁlter mask FF P3 (reduction factor 20)
23
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